Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative bioavailability of cefdinir for oral
suspension 250 mg/5mL (manufactured and distributed by TEVA Pharmaceuticals USA) with that of
OMNICEF® for oral suspension, 250 mg/5mL (Abbott) in healthy, adult, non-smoking subjects
under non-fasting conditions.